Clinical Features of Huntington's Disease
- PMID: 29427096
- DOI: 10.1007/978-3-319-71779-1_1
Clinical Features of Huntington's Disease
Abstract
Huntington's disease (HD) is the most common monogenic neurodegenerative disease and the commonest genetic dementia in the developed world. With autosomal dominant inheritance, typically mid-life onset, and unrelenting progressive motor, cognitive and psychiatric symptoms over 15-20 years, its impact on patients and their families is devastating. The causative genetic mutation is an expanded CAG trinucleotide repeat in the gene encoding the Huntingtin protein, which leads to a prolonged polyglutamine stretch at the N-terminus of the protein. Since the discovery of the gene over 20 years ago much progress has been made in HD research, and although there are currently no disease-modifying treatments available, there are a number of exciting potential therapeutic developments in the pipeline. In this chapter we discuss the epidemiology, genetics and pathogenesis of HD as well as the clinical presentation and management of HD, which is currently focused on symptomatic treatment. The principles of genetic testing for HD are also explained. Recent developments in therapeutics research, including gene silencing and targeted small molecule approaches are also discussed, as well as the search for HD biomarkers that will assist the validation of these potentially new treatments.
Keywords: Biomarkers; Genetics; Huntington’s disease; Management; Symptoms; Therapeutics.
Similar articles
-
Huntington's Disease: Relationship Between Phenotype and Genotype.Mol Neurobiol. 2017 Jan;54(1):342-348. doi: 10.1007/s12035-015-9662-8. Epub 2016 Jan 7. Mol Neurobiol. 2017. PMID: 26742514 Review.
-
Huntington's disease: clinical presentation and treatment.Int Rev Neurobiol. 2011;98:297-323. doi: 10.1016/B978-0-12-381328-2.00013-4. Int Rev Neurobiol. 2011. PMID: 21907093 Review.
-
Huntington's disease: a clinical review.Eur J Neurol. 2018 Jan;25(1):24-34. doi: 10.1111/ene.13413. Epub 2017 Sep 22. Eur J Neurol. 2018. PMID: 28817209 Review.
-
Immunomodulatory Strategies for Huntington's Disease Treatment.CNS Neurol Disord Drug Targets. 2017;16(8):936-944. doi: 10.2174/1871527316666170613084801. CNS Neurol Disord Drug Targets. 2017. PMID: 28606048 Review.
-
Clinical Aspects of Huntington's Disease.Curr Top Behav Neurosci. 2015;22:3-31. doi: 10.1007/7854_2013_238. Curr Top Behav Neurosci. 2015. PMID: 23975844 Review.
Cited by
-
Gut Bacteria Regulate the Pathogenesis of Huntington's Disease in Drosophila Model.Front Neurosci. 2022 Jun 2;16:902205. doi: 10.3389/fnins.2022.902205. eCollection 2022. Front Neurosci. 2022. PMID: 35757549 Free PMC article.
-
Peroxiredoxins in Neurodegenerative Diseases.Antioxidants (Basel). 2020 Nov 30;9(12):1203. doi: 10.3390/antiox9121203. Antioxidants (Basel). 2020. PMID: 33265993 Free PMC article. Review.
-
Network propagation for GWAS analysis: a practical guide to leveraging molecular networks for disease gene discovery.Brief Bioinform. 2024 Jan 22;25(2):bbae014. doi: 10.1093/bib/bbae014. Brief Bioinform. 2024. PMID: 38340090 Free PMC article. Review.
-
A survey of protein interactions and posttranslational modifications that influence the polyglutamine diseases.Front Mol Neurosci. 2022 Sep 14;15:974167. doi: 10.3389/fnmol.2022.974167. eCollection 2022. Front Mol Neurosci. 2022. PMID: 36187346 Free PMC article. Review.
-
CAG repeat instability in embryonic stem cells and derivative spermatogenic cells of transgenic Huntington's disease monkey.J Assist Reprod Genet. 2021 May;38(5):1215-1229. doi: 10.1007/s10815-021-02106-3. Epub 2021 Feb 20. J Assist Reprod Genet. 2021. PMID: 33611676 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases